Hepatocellular carcinoma (HCC) is the most common primary liver cancer, and the incidence of HCC is increasing. Recently, cancer immunotherapy has emerged as an efficient treatment against some cancers. Here we have used a mouse model of mutagen-induced HCC to explore the therapeutic usefulness of targeting the DNA-activated STING pathway in HCC. STING-deficient mice exhibited unaltered initial development of HCC, but had higher number of large tumors at late stages of disease. In the liver of STING-deficient HCC mice, we observed reduced levels of phospho-STAT1, autophagy, and cleaved caspase3. These responses were activated in the liver by treatment with a cyclic dinucleotide (CDN) STING agonist. Importantly, CDN treatment of mice after HCC development efficiently reduced tumor size. Initiation of CDN treatment at an even later stage of disease to allow HCC detection by MR scanning revealed that the majority of tumors regressed in response to CDN, but new tumors were also detected, which were unresponsive to CDN treatment. Overall, the modulation of the STING pathway affects the development of HCC, and holds promise for a use as a treatment of this disease, most likely in combination with other immunomodulatory treatments such as PD1 inhibitors or with standard of care.
Introduction
Hepatocellular carcinoma (HCC) is the most common form of primary liver cancer, and the incidence of HCC is increasing [1] . This is related to the increase of obesity and symptoms that are related to chronic liver inflammation. Liver inflammation is a hallmark of HCC progression due to induction of cell death and compensatory proliferation of hepatocytes [2] . At the same time, it has become clear that some types of inflammation have antitumor functions in HCC progression. Innate immune responses to RNA have been shown to decrease HCC progression in in vivo models, and in a cohort study of disease progression in HCC patients [3] . Immunological RNA sensing in the cytoplasm induces type I interferon (IFN) and expression of a cascade of IFN-stimulated genes (ISG), which induce antitumor activity [4] .
Similar to specific forms of RNA in the cytoplasm, cytoplasmic localization of DNA is a danger signal, leading to related types of responses, with notably the IFN system being strongly activated [5] . More recently, it has emerged that cytoplasmic DNA also induces other types of responses, including autophagy, cell death, and promotion of adaptive immune responses [6] [7] [8] . DNA sensors recognize DNA from pathogens or misslocated self-DNA in the cytosol. The main receptor of the DNA sensing pathway is cyclic GMP-AMP synthase (cGAS), which synthetizes the cyclic dinucleotide (CDN) secondary messenger cyclic GMP-AMP (2′3′-cGAMP) upon DNA recognition [5] . 2′3′-cGAMP binds to stimulator of IFN genes (STING), which dimerizes and recruits TANK-binding kinase 1 and subsequently IFN-regulatory factor 3, eventually leading to transcriptional activation of the type I IFN genes [5] . Interestingly, hepatocytes do not express STING, and therefore cannot activate the pathway [9] . However, the nonparenchymal cells of the liver are capable of sensing cytoplasmic DNA, including Kupffer cells [9] .
Recently, it has emerged that the STING pathway has a tumor suppressor function [10] . Accordingly, many cancer cell lines have downmodulated the cGAS-STING pathway through reduced gene expression of central genes, such as STING, or by oncogenes expressed by the tumor cells [11, 12] . Mice deficient for STING show elevated susceptibility to a panel of experimental cancers [13] [14] [15] . On the other hand, it has also been reported that STINGdependent inflammation can contribute to promote skin carcinogenesis [16] . Administration of 2′3′-cGAMP or synthetic CDNs has proven to have antitumor function. In syngeneic xenograft models of different tumors, immunecompetent mice have a reduced burden of both primary and secondary tumors following CDN treatment [17] . However, immune-deficient mice failed to clear the tumor, highlighting the importance of the immune system [17] . CDN treatment is therefore a potential cancer immunotherapy, and it has been reported that the STING signaling pathway promotes beneficial T-cell response [18, 19] . On the other hand, the STING pathway appears to promote the inhibition of proliferation and apoptosis in T cells, which could potentially impair antitumor activity [20, 21] . Autophagy is one biological process stimulated by STING agonists [22] . Autophagy is generally seen as a tumor suppressor in HCC, and mice deficient for either ATG5 or ATG7 spontaneously develop benign liver tumors [23] . Autophagy is crucial in cancer immunotherapy for presentation of tumor antigens on MHC to generate T cells responses [23] . Since, the STING pathway induces many different biological functions, the impact of CDN treatment most likely differs among various cancer forms.
Here we have evaluated the role of STING signaling in the control of HCC induced by the hepatocyte-specific mutagen diethylnitrosamine (DEN), and have explored the anticancer activity of CDNs in this model. We observed that lack of STING accelerated tumor progression, and CDN treatment reduced tumor volume. Moreover, CDNs promoted cell death, autophagy, and IFN responses in the liver, and these responses were impaired in DEN-induced HCC mice lacking STING. On the other hand, CDN treatment reduced T-cell numbers. Thus, although the STING pathway promotes both pro-and antitumor activities, it is involved in control of liver cancer, and could potentially be targeted therapeutically to promote the antitumor immune response.
Methods

Animals
We used age-matched male mice, bred on a C57BL/6 (WT), STING gt/gt (STING-Goldenticket; C57BL/6J-Tmem173 gt /J) and cGAS −/− (B6(C)-Mb21d1 tm1d(EUCOMM)Hmgu /J). All experiments were carried out at Aarhus University with permission of the Danish government authorities and in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals, EEC Council Directive 2010/63/EU. HCC were induced in 2-week-old male mice with 25 mg/ kg DEN in saline. Short-term experiments were carried out in 8-week-old male treated with 100 mg/kg DEN. 3′3′-cAIMP were administrated IP in saline buffer at 125 µg/ mouse in the short-term experiments. For the HCC treatment, mice were injected three times a week for 4 weeks with 2 µg/g of 3′3′-cAIMP (Invivogen, tlrl-nacai) in saline.
The depletion of Kupffer cells was performed with liposome-encapsulated clodronate or PBS as control. Mice were injected i.v. with 200 µl liposome-encapsulated clodronate (5 mg/ml) or liposome-encapsulated PBS (Liposomatechnology). The mice were subjected to further treatment 3 days after the delivery of liposomes.
MicroPET/MR
The mice underwent functional positron emission tomography (PET) and anatomical magnetic resonance imaging (MRI) 1T (Mediso Medical Imaging Systems, Budapest, Hungary). Anesthesia was initiated using isoflurane with the mouse being placed in an acrylic glass chamber and maintained with a respiration mask during the scan. A bolus of [18F]-flurodeoxyglucose (FDG) (∼15 MBq/animal) was injected via the tail vein, and PET scanning was performed 60 min after the injection for 10 min, followed by a 30 min MRI-scan.
A static PET image was reconstructed with a threedimensional ordered subset expectation algorithm (Tera-Tomo 3D; Mediso Medical Imaging Systems) with four iterations and six subsets and a voxel size of 0.4 × 0.4 × 0.4 mm 3 . The data were corrected for dead-time, decay, and randoms using delayed coincidence window without corrections for attenuation and scatter. A specialist in nuclear medicine identified tumors by visual inspection of the PET/ MRI-scans using the software PMOD 3.6 (PMOD Technologies Ltd., Zurich, Switzerland). Borders of the tumors were then drawn manually, and their volume was calculated using HERMES (Hermes Medical Solutions, Stockholm, Sweden).
Cell culture work
Primary hepatocytes and Kupffer cells were isolated from the mice using a two-step perfusion of the liver: first, with perfusion buffer, followed by digestion buffer (Gibco). Single cells were filtered through a 100-μm mesh, and hepatocytes were pelleted following three centrifugations at 50 × g for 4 min. The supernatants were collected for obtaining immune cells and added to tissue culture dishes for 8 min to allow the Kupffer cells to adhere. Adherent cells were washed and incubated with Dulbecco's modified Eagle's medium (DMEM), containing antibiotics and fetal calf serum (FCS). Live hepatocytes were isolated through gradient centrifugation in Percoll, washed, counted, and plated on precoated plates in DMEM containing antibiotics and FCS. All hepatocyte cell lines were maintained in DMEM containing antibiotics and FCS. THP-1 cells grew in RPMI containing antibiotics and FCS. The cells were stimulated with either 10-100 µg/ml of 3′3′-cAIMP (Invivogen, tlrl-nacai), 25 U/ml of IFN-α2a (PBL Assay Science), 25 ng/ml TNF-α (PeproTech 300-01 A) or 4 μg poly (I:C), and 2 μl Lipofectamine/ml medium.
Immunoblotting
Liver tissues or cells were lysed in RIPA buffer in the presence of protease and phosphatase inhibitors and were sonicated before being subjected to SDS-PAGE and immunoblotting. The blots were blocked either with 2.5% BSA or 5% dry milk in TBS containing 0.1% tween20 before being probed with primary antibodies. The following antibodies were used: STING (RD AF6516, CS13647, CS50494), ISG15 (CS2743S), viperin (Millipore, MABF106), pSTAT1 (CS7649), pSTAT3 (CS9131, cleaved caspase3 (CS9661), LC3 (CS2775), and vinculin (Sigma, V9131). Appropriate peroxidase-conjugated secondary antibodies were used and developed (Jackson ImmunoResearch).
Immunohistochemistry
Tissues were fixed in 10% formaldehyde o/n and embedded in paraffin and cut into 4 µm sections. Antigen retrieval was performed at 100°C in a citrate buffer, pH 6 for 20 min. Sections were blocked in 2.5% BSA in TBS + 0.1% tween20 and the following primary antibodies were used: pSTAT1 (CS7649), viperin (Millipore, MABF106), CD3 (SC-1127), CD4 (CS25229), CD8 (CS98941), Sting (CS50494), F4/80 (AB6640, CS70076), Ki67 (Sigma Sp6), cleaved caspase3 (CS9661), and p-yH2AX (Millipore JBW301). Appropriate secondary antibodies coupled to HRP were used. The counterstaining was performed with hematoxylin.
Quantitative RT-PCR
The total RNA was extracted from the liver with TRIzol (Invitrogen) and homogenized according to the manufacturer's instructions. RNA was treated with DNase (Invitrogen) and 50 ng total RNA was used per qRT-PCR reaction. The total RNA of the cells was extracted with RNeasy kit from Qiagen according to the manufacturer's instructions. cDNA was synthesized prior to qRT-PCR with site specific primers in the same reaction tube for the qRT-PCR for 30 min at 48 C. SYBR Green III (Stratagene) was used according to the manufacturer's recommendations for the qRT-PCR reaction and 40 cycles of amplification were performed. All data were analyzed using the ΔΔCT method and normalized to β-actin. For primers see Table S1 .
ELISA
Alpha fetal protein (AFP) was measured from serum with Mouse alpha-Fetoprotein/AFP Quantikine ELISA Kit (MAFP00) according to the manufacturer's instructions.
Flow cytometry and cell sorting
Immune cells were isolated from the liver and spleen by filtering the samples through a 100-µm (liver) or a 70-μm (spleen) cell strainer. The hepatocytes were pelleted by centrifugation for 4 min at 50 g, and the supernatant containing the immune cells was collected. Lymphocytes were isolated from whole blood by Ficoll separation. Cells were incubated with FC-Block (BD) and the following antibodies against immune cell surface markers: CD3, CD4, CD8, and CD45 (all from BD Bioscience). Data were acquired on a NovoCyte (ACEA Biosciences) and analyzed using FlowJo.
Statistics
For statistical analysis of data, an unpaired two-tailed Student's t test was used. p values ≤ 0.05 were considered to reflect statistically significant differences between compared groups. The data shown are representative of one out of three or more experiments.
Study approval
All described animal experiments have been reviewed and approved by Danish government authorities and hence comply with Danish laws (The Animal Experiments Inspectorate, Slotsholmsgade 10, 1216 København K, Denmark).
Results
STING agonists enable cross talk between hepatocytes and immune cells
The cGAS-STING pathway is hypoactive in hepatocytes, due to the lack of STING expression, but the nonparenchymal liver cells such as Kupffer cells are capable of sensing cytoplasmic DNA [9] . Recently, there has been an extensive interest in the role of the STING pathway in cancer and the application of synthetic STING ligands as potential therapeutics treatment [17, 18, 24] . It is not known whether STING is expressed in transformed hepatocytes, which could occur as a consequence of the dedifferentiation of the cells. An analysis of mutations in the genes encoding cGAS and STING in HCC in the human genome atlas database revealed that less than 1% of cases have mutations in these genes. Moreover, the human protein atlas contains 12 HCC samples stained for STING expression and the majority stains negative ( Fig. 1a ). Samples with positive staining contained only a few STING positive hepatocytes. We did not observe positive staining in the murine liver cancer cells in agreement with the human data from the human protein atlas ( Fig. S1A ). Next, we screened a panel of human HCC cell lines for STING expression and activation after the stimulation of the pathway. Out of five human cancer hepatocyte cell lines, only one showed significant expression of STING and induction of ISGs after activation of STING by the agonist 3′3′-cAIMP ( Fig. 1b ). In parallel, murine Kupffer cells isolated from neoplastic livers were stimulated with 3′3′-cAIMP and compared with the murine HCC cell line AML12. STING expression and ISG production was much higher in the Kupffer cells from a murine HCC liver compared with the HCC cells ( Fig. 1c ). We observed reduced STING protein levels after agonist treatment ( Fig. 1c ), in agreement with the described negative feedback loop involving STING degradation [22] . To explore whether Kupffer cells contribute to the type I IFN response in vivo after stimulation with 3′3′-cAIMP, we depleted Kupffer cells in living mice by liposome delivery of clodronate [25] . Staining for the macrophage marker F4/ 80 confirmed a loss of Kupffer cells in the liver 3 days after depletion (Fig. 1d ). The mice were hereafter stimulated with 3′3′-cAIMP for 4 h before the IFNβ levels and viperin expression were analyzed. Mice depleted of Kupffer cells had decreased levels of IFNβ in the serum and viperin expression in the liver (Fig. 1e, f) . These data show that an elevation of STING expression in transformed hepatocytes occurs rarely, and the robust response to STING agonists in neoplastic livers occurs in nonparenchymal liver cells such as Kupffer cells.
We were interested in how the STING pathway affects the development and control of HCC, since here STING is differentially expressed in the various cell types involved in the tumor environment. First, we treated wild-type mice with the synthetic STING agonist 3′3′-cAIMP and analyzed the IFN response by IHC. We observed strong pSTAT1 in nonparenchymal cells and decreased levels in hepatocytes. The expression of the downstream ISG viperin was seen in all cells (Fig. 2a ). The increased levels of pSTAT1 and viperin were confirmed by western blot analysis (Fig. 2b) . We also observed a minor elevation in the levels of cleaved caspase3, as has been observed before when STING pathway is activated ( Fig. 2b) [21, 26] . Furthermore, we observed increased autophagy in the liver after 3′3′-cAIMP stimulation, as determined by convention of LC3-I to LC3II (Fig. 2b) . In contrast, stimulation of primary hepatocytes in vitro did not activate the STING pathway showing the importance of cross talk between different cells types in the liver (Fig. 2c ). An analysis of the expression of the T-cell attracting chemokine Cxcl10 revealed an induction upon STING activation together with MHCI (H-2D-b), which presents antigens to CD8 T cells (Fig. 2d ). In vitro stimulation of the human macrophage-like cell line THP-1 with 3′3′-cAIMP led to high expression levels of T-cell attracting chemokines ( Fig. 2e ), and also IFNa/b and NFkB activation, which induces inflammation and cell death pathways ( Fig. S2A ). Furthermore, media from Huh7 cells subjected to DNA damaging also induced gene transcription in THP-1 driven by the IFN-sensitive responsive element in a STINGdependent manner, indicating that cytoplasmic content from dying cells can activated STING pathway in bystander cells (Fig. S2B) . Interestingly, the human hepatocyte cell line Huh7 was highly sensitive to a treatment with IFNα or TNFα, and the latter was observed to activate the apoptotic caspase3 (Fig. 2f) . Thus, stimulation of the STING pathway 
Lack of STING promotes HCC development induced by a genotoxic agent in mice
To address the function of the STING pathway in HCC progression we used the DEN-induced liver cancer model, and took advantage of STING-deficient mice (Sting gt/gt ). Eight weeks old mice were treated with DEN, which induces DNA damage specifically in hepatocytes [2] . DNA damage, apoptosis, and proliferation were assessed at 48 and 72 h after DEN treatment ( Figs. 3a and S3 ). Wild-type and STING-deficient mice showed the same degree of DNA damage and apoptosis in the liver and proliferation was not impaired. Similarly, expression of classical ISGs and cytokines were increased after the administration of DEN but not affected by the STING deficiency ( Figs. 3b and S3 ). These data indicate that the DNA sensing cGAS-STING pathway is dispensable for the first events in a carcinogentriggered induction of HCC.
To address the involvement of STING-dependent signaling in HCC progression, 2 weeks old mice were injected with DEN. The mice were followed for 8 months, and their survival was monitored. All wildtype mice exhibited no overt signs of disease over this period, but three STING-deficient mice had to be sacrificed, since humane endpoint criteria have been reached (Fig. 3c ). An examination of the surface of the livers at 8 months post DEN treatment revealed a similar number of nodules (HCC or a precancer lesion) between the two genotypes ( Fig. 3d ). However, the livers from the STING-deficient mice had larger tumors than the wildtype mice (Fig. 3e, f) . Serum AFP levels were slightly elevated in Sting-deficient mice, reflecting the increased aggressiveness of the tumors (Fig. 3g) . These data indicate that STING-dependent signaling is involved in suppression of HCC progression.
Altered immune activity in STING-deficient HCC livers
The examination of the HCC liver tissue 8 months after DEN treatment identified mostly clear cells in both genotypes [27] . An increased proliferation was observed in the tumors, as well as an infiltration of T cells (Fig. 4a ). Figs. 4a and S4 ). Western blot of liver tissue showed decreased pSTAT1 and pSTAT3 in samples from the STING-deficient mice, indicating an impaired immune activation (Fig. 4b) . Interestingly, levels of LC3-I and II were decreased in liver samples from Fig. 3 Loss of STING increases tumor size but is dispensable for HCC initiation. Wild-type and STING-deficient mice were treated with DEN at 8 weeks of age. a IHC for DNA damage (p-yH2AX) and cleaved caspase3 (48 h after DEN administration) and cell proliferation (Ki67, 72 h post DEN treatment) (n = 6). b RNA was isolated from total liver at 24 and 48 h post treatment and qRT-PCR was performed for Isg15 and Isg56 (n = 3-6). Two weeks old wild-type and STING-deficient mice were treated with DEN to induce HCC. Samples were isolated 8 months later for analysis. c Kaplan-Maier plot for survival (p = 0.07, n = 10). d Quantification of surface nodules (n = 10). e Image of surface tumors from a wild-type and a STING-deficient liver 8 months after DEN treatment. Dotted black lines mark the tumors. f Quantification of surface tumor size (n = 10, p < 0.05). g AFP was measured in the serum (p < 0.05, n = 10) STING-deficient HCC mice, indicating a role of STING in autophagy in HCC livers (Fig. 4b) . Accordingly, the STING deficiency decreased DNA-damage-induced autophagy in primary MEFs (Fig. S5 ). In addition, we observed a tendency toward lower levels of cleaved caspase3 in STINGdeficient HCC livers compared with wild-type mice (Fig.  4b) . To address if there were differences in immune activities between the genotypes in the tumor microenvironment or the nontumor liver tissue of HCC-bearing mice, tumors and nontumorigenic tissues were isolated from the livers for gene expression analysis. Tumor tissues had in general increased levels of inflammatory genes compared with nontumor tissues (Fig. 4c ). An increased inflammation was also evident in STING-deficient tumors including ISGs, which are induced by STAT1-dependent pathways. Interestingly, PD-L1 was slightly increased in the tumors. PD- Fig. 4 Impaired inflammatory signaling and autophagy in STINGdeficient livers containing HCC. Wild-type (WT) and STING-deficient mice were treated with DEN to induce HCC formation. Samples were harvested for analysis 8 months after DEN treatment. a Representative histological sections of HCC were stained for H&E, Ki67, CD3, and CD8 (n = 10). The dotted lines mark the tumor borders (T) and arrowheads mark positive cells. b Western blot analysis of whole liver lysates for pSTAT1, pSTAT3, STING, LC3, and cleaved caspase3 (CC3). Vinculin was used as loading control (n = 4, p < 0.05%). c Tumors and nontumor tissues were isolated from liver and RNA was isolated. qRT-PCR for immune-related genes were performed for both wild-type and STING-deficient mice (n = 3, *p < 0.05%). d Histological sections of HCC stained for viperin (brown) (n = 10). The dotted lines mark the tumor borders (T) L1 is an ISG [28, 29] and is known to decrease tumor immune surveillance by the exhaustion of cytotoxic T cells [30, 31] . Immunohistochemistry for the expression of the ISG viperin showed a very low staining in the tumor, irrespective of genotype (Fig. 4d) . Interestingly, we observed strong viperin expression levels at the interphase between tumor and the normal tissue in wild-type mice, and less in STING-deficient mice (Fig. 4d) . These data demonstrate that STING-deficient HCC mice have altered IFN signaling, cell death, and autophagy in the liver. 
Staining for CD4 and CD8 positive T cells revealed that CD8 T cells (cytotoxic T cells) are the predominant T-cell subtypes in the HCC tumors (
CDN treatment of tumor-bearing HCC mice reduces tumor burden
An activation of the STING pathway has been connected to tumor surveillance by the induction of cell death, and the promotion of T-cell responses [18, 19] . To evaluate whether a treatment with CDNs impairs tumor development, mice with HCC received CDNs systemically. To ensure that the natural CDN production would not interfere with the experiment, we took advantage of cGAS deficient mice, which cannot generate 2′3′-cGAMP [32] . DEN treatment was applied to the mice at 2 weeks of age, and at 8 months of age 3′3′-cAIMP was administrated systemically with a regimen of three times per week for 4 weeks (Fig. 5a ). Hereafter the tumor burden was assessed. The optimal dosing of 3′3′-cAIMP had been previously optimized in an in vivo orthotopic syngeneic C57Bl/6 model, ensuring that this dose induces a strong ISG expression in the liver (Fig.  S6A ). The number of liver surface nodules was the same between mock and 3′3′-cAIMP-treated mice (Fig. 5b) . However, the observed nodules were significantly smaller in the CDN-treated mice (Fig. 5c ). At the time of analysis, it had not led to differences in circulating AFP between the two groups (Fig. 5d ), but the mice did show an increased expression of ISG (Fig. S6B, C) . As the CDN treatment has been associated with T cells recruitment [33] , the livers were analyzed for presence of T cells. Surprisingly, following CDN treatment, we observed a significant decrease in CD8 positive T cells in the liver (Fig. 5e) , and observed a similar tendency in CD3 and CD4 positive cells, when gated on total lymphocytes. The same observation was done when analyzing T cells in the spleen, but not in the blood Fig. 6 HCC regression after 3′3′-cAIMP application. a Wild-type and cGas −/− mice were treated with DEN at day P15. At 10 months of age, mice were administrated 3′3′-cAIMP 2 mg/kg three times per week for 4 weeks and left untreated for another 4 weeks. Mice were scanned three times at age 10, 11, and 12 months of age. Shown are representative MR scan of liver tumors that b respond or c did not respond to 3′3′-cAIMP treatment. d In total, 23 tumors were scanned two or more times. Among those, the volume decreased for 13 tumors. e Overall, 21 tumors were monitored during the treatment period. Among those, ten regressed during the period and could not be identified at the last scan. f Western blotting analysis of STING expression in resistant HCC tumors and normal liver tissues (control). Vinculin was used as loading control. g IHC for STING expression in liver section of normal tissues (control), nontumor and tumor tissues. Arrowheads mark STING positive cells (n = 5) ( Fig. S6D) . To evaluate if the overall decrease of lymphocytes in the liver also decreases the number of these cells in the tumors, IHC for CD8 was performed on the liver sections. CD8 positive lymphocytes were present in HCC at this time point, and samples from mice treated with CDN had a clear tendency toward increased number of CD8 positive cells in the tumors (Fig. 5f) . Evaluating for infiltrating macrophages showed a decrease in HCC and administration of CDN did not increase this cell population in the tumors (Fig. 5f) . In contrast, CDN-treated mice had increased numbers of cleaved caspase3 positive cells in HCC tumors, showing increased apoptotic cell death in the tumors after treatment (Fig. 5f) .
The decrease in tumor size after 3′3′-cAIMP treatment suggested that the CDN has induced antitumor activity. To examine if the anti-HCC program activated by CDNs acted together with other host antitumor activities in the microenvironment, HCC mice were left untreated for 1 month after completion of the CDN treatment before the tumor burden was assessed (Fig. 5g) . The assessment of the surface tumors showed decreased numbers in the 3′3′-cAIMP-treated mice and a similar tendency for AFP ( Fig. 5h, i) . To examine the tumors at the microscopic level, liver sections were analyzed by IHC. The mock-treat mice had a variety of large and small HCC tumors throughout the liver lobes, whereas the CDN-treated mice showed clearly reduced tumor size ( Fig. 5j ). Some areas could be identified with increased proliferation, but these areas did not show any features of HCC (Fig. 5j ). However, in the CDN-treated mice, we still observed a few large tumors, suggesting that some tumors were unresponsive to CDN treatment (Fig. 5j ). In these tumors, we observed a clear tendency toward fewer infiltrating T cells. Overall, the systemic administration of CDN decreased the HCC burden.
STING agonists induce regression of a large subset of HCC tumors
To gain insights into the effects and dynamics of HCC tumors following CDN treatment, individual tumors were followed by 18 F-FDG microPET/MR scanning throughout the treatment period (Fig. 6a ). Previous work in patients has revealed that spontaneous regression of tumors in HCC patients occurs with a frequency below 1:60,000 [34, 35] . To be able to identify the tumors by scanning, we used mice that had received DEN treatment 10 months before, thus having developed larger tumors. The mice were scanned at the initiation and termination of CDN treatment as well as 1 month post CDN treatment, i.e., 10, 11, and 12 months after DEN treatment. Five mice were scanned with MRI, and we identified 14 tumors before the initiation of the treatment ( Table 1 ). The scanning revealed that the volume of nine initially detected tumors regressed to undetectable levels between the first and third scan, while two tumors remained unchanged. On the other hand, three of the initially detected tumors grew despite CDN treatment (Fig. 6b , c, Tables 1 and S7 ). Furthermore, new tumors also appeared during the observation period. Of those, three responded to CDN treatment and six did not respond to the treatment (Table 1 ). For 4 of the 5 mice followed (#1-4), in 13 of 17 tumors the volume regressed or remained unchanged following CDN treatment, while 4 out of 17 tumors grew continuously. One tumor showed initial regression followed by remission. The tumors in the fifth mouse (cGas −/− #5) were generally refractory to CDN treatment. Overall, the majority of the followed tumors responded to the treatment (Fig. 6d ) and half of them regressed to a size not detectable by MRI scanning (Fig. 6e) . A dissection of the liver confirmed that most of the tumors had completely regressed, although a minor subset of the tumors no longer detectable by microPET/MRI scanning could still be visually identified as small lesions (data not shown). The tumors that did not response to the treatment continued to grow over the period, which result in an overall increased tumor volume (Table 1 ). The nonresponder tumors were analyzed for the expression of STING to test the possibility that lower expression could explain the lack of responsiveness. Surprisingly, western blotting for STING showed increased level when compared with normal liver or nontreated HCCbearing mice (Figs. 6f and S1). Furthermore, IHC for STING on samples with high levels of STING showed increased levels in nonparenchymal cells (Fig. 6g ).
Prior to the scanning, the mice were administrated 18 F-FDG as a tracer for increased glucose uptake. Metastatic tumors generally have an increased metabolism and can therefore be detected by 18 F-FDG and PET scanning. None of the mice that were subjected to the scanning had developed metastasis or other primary tumor besides HCC. 18 F-FDG PET has a sensitivity of ∼50% in human HCC due to glucose-6-phosphatase activity [36] . In concordance, only a few of present tumors showed increased 18 F-FDG-uptake in the second scan after 3′3′-cAIMP administration (Fig. S8 ). Whether this was due to increased metabolism, hypoxia, or immune response was not examined. Overall, these data show that most HCC tumors regress in response to STING agonist treatment.
Discussion
Here we show that the STING pathway suppresses HCC progression. This is based on observations that STINGdeficient mice show an increased tumor load, and CDN treatment reduces the tumor burden. Interestingly, we observed that tumor incidents were not affected by a modulation of the STING pathway, which suggests that immunological DNA sensing does not affect the initial stages of HCC development. Chronic liver inflammation driven by obesity or hepatitis virus infection has previously been reported to promote HCC formation. Takahashi et al. showed that loss of STING decreases HCC burden in a mouse model based on treatment with mutagen in combination with high fat diet [37] . This phenotype resulted from a lower inflammation in the STING-deficient mice. These data are in line with our present data and suggests that the role of the STING pathway in HCC depends on the local inflammatory environment in the developing tumor. Under conditions with low constitutive inflammation, STING plays a protective role in HCC.
As hepatocytes do not contain a functional STING pathway, the antitumor action is a noncell-autonomous function carried out by the nonparenchymal liver cells. Here, the nonparenchymal cells are important in detecting cell deaths and DNA damage, and it is possible that the cGAS-STING pathway is activated by DNA released from dying cells (Fig. 7) . Macrophages, such as Kupffer cells, are capable of producing large amounts of cytokines, including T-cell attracting chemokines, after sensing DNA in the cytosol (Fig. 7) [38] . Through this means, the nonparenchymal cell compartment is able to recruit cells of the adaptive immune system to the area where cytosolic DNA has been sensed ( Fig. 7) [39] . More recently, novel activities have been reported to be induced by STING-dependent signaling, including autophagy and apoptosis, both of which are well established to be involved in antitumor responses [18] [19] [20] [21] [22] 40] . For instance, autophagy has antitumor function in HCC, and mice deficient for the autophagy gene Atg5 and 7 develop spontaneous benign liver tumors. HCC-bearing STING-deficient mice show decreased autophagy in the liver. Hence, STING-deficient mice are impaired in several pathways known to exhibit antitumor activity. cytokine production, which result in decreased STAT signaling and cell death. c Administration of the STING agonist 3′3′-cAIMP increases cytokine expression, particularly type I IFN. This is followed by an increase in ISG expression and release of other cytokines to recruit lymphocytes. Furthermore, 3′3′-cAIMP treatment increases hepatocyte cell death STING agonists have recently been tested in cancer immunotherapy and clinical trials are ongoing [41] . The effect of the first STING agonist DMXAA was tested before the target protein STING was discovered. However, the compound failed in clinical trials, since human STING is not activated by DMXAA [42] . The new generation of STING agonists are CDNs, which have proven to induce cell death in tumors and stimulate adaptive immune response against the tumor when injected intratumorally [33] . Here we have delivered CDNs systemically to address whether we could treat multiple tumors that are not suitable for direct injection. We therefore titrated the dose of CDNs and the treatment period to gain full effect but with minimal side effect. We observed that the mice lost weight during treatment period and few developed ascites in the last week of treatment (Fig.  S9) . These ascites decreased hereafter over the following weeks. Thus, CDN treatment has a transient toxic effect during the treatment period as seen for other cancer immunotherapies reagents used in the clinic [43] .
The application of cancer immunotherapy has variable success, and CDNs have mainly been tested in xenograft models, where the tumors are homogenous. We have applied CDNs treatment to HCC that has been chemically induced by a genotoxic agent that generates multiple tumors, which contain a heterogenic set of mutations [44] . This mimics a more natural tumor incident, even through multiple primary tumors are less common. The treatment of HCC with 3′3′-cAIMP reduces the tumor burden, but could not clear the animals for HCC. microPET/MR scan revealed that most tumors responded directly to 3′3′-cAIMP treatment, and that the effect remained after the treatment period. However, the scanning also showed that not all tumors responded to treatment. It has also emerged that immunotherapy increases mutations in the tumor, reflecting the tumors' ability to escape the treatment [45, 46] . We speculate that nonresponsive tumors hold different mutations than responsive tumors, thus showing different susceptibilities to an elimination by infiltrating T cells. Spontaneous tumor regression is a very rare event in HCC and occurs in 1 out of 60,000-100,000 tumors [34, 35] . It is therefore very interesting that 3′3′-cAIMP treatment could induce regression of~50% of the tumors present at the start of treatment.
An exhaustion of T cells is a common phenomenon in cancer immunotherapy, and the PD1/PD-L1 inhibitor has proven to be beneficial to overcome this problem. The administration of 3′3′-cAIMP decreased CD8 T-cell numbers in the liver over the treatment period ( Fig. 5e ) and also in short-term experiments, and it has been shown that CDNs can reduce the proliferation and even induce cell death in T cell [20] . A decrease in cytotoxic T cells after 3′3′-cAIMP administration could have a negative effect on the overall antitumor response. However, a combination of 2′3′-cGAMP treatment with PD-L1 inhibitor has shown promising results in a xenograft model [47] . Further work should focus on combining 3′3′-cAIMP treatment with PD-L1 inhibitor to address a possible synergy in treatment of HCC. This should also be combined with more traditional treatments such as radiation or chemotherapy. Irradiated and dying cells release cellular contents that can activated the immune response ( Fig. 2S) and possibly prime the immune system to target the cancer cells. Therefore, cancer immunotherapy could be combined with more traditional treatment options.
